Potentially good news for research into Alzheimer’s Disease.  AstraZeneca is said to be talking to other pharmaceutical companies as it seeks a partnering deal for its experimental Alzheimer’s drug.  Briggs Morrison, global head of medicines development, says a deal would share development of AstraZeneca’s so called BACE inhibitor drug, which is set to enter late stage Phase 3 development.  AstraZeneca believes its BACE inhibitor could potentially sell as much as $5 billion a year, but it gives only a 9 percent chance of success on a risk adjusted basis given the high failure rate in the disease sector. The British Company is fighting a $106 billion bid approach from fellow drug giant Pfizer.